QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ZYME

QT60Zymeworks Inc.
NASDAQ·Healthcare·Biotechnology·Canada
Latest market price
23.14
+0.00%
OverviewShort InterestFilings
ZYMEQT60Zymeworks Inc.·NASDAQ
OverviewShort InterestFilings
23.14+0.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)-1.37
Insider Own49.22%
Shs Outstand73.02M
Perf Week0.74%
Market Cap1.70BForward P/E50.15EPS next Y0.46Insider Trans0.81%Shs Float-Perf Month-5.16%
Enterprise Value1.48BPEG0.84EPS next Q-0.39Inst Own-Short Float-Perf Quarter-3.18%
Income-101128555.00P/S20.95EPS this Y199.76%Inst Trans-Short Ratio-Perf Half Y-10.48%
Sales81.26MP/B10.56EPS next Y-66.24%ROA-21.47%Short Interest-Perf YTD-12.12%
Book/sh2.25P/C-EPS next 5Y-14.32%ROE-37.79%52W High29.75 -22.22%Perf Year89.05%
Cash/sh5.00P/FCF-EPS past 3/5Y-ROIC-25.26%52W Low11.51 101.04%Perf 3Y-
Dividend Est.-EV/EBITDA-15.64Sales past 3/5Y-36.40% 22.14%Gross Margin94.42%Volatility2.41% 2.55%Perf 5Y-
Dividend TTM-EV/Sales18.15EPS Y/Y TTM15.43%Oper. Margin-140.35%ATR (14)0.98Perf 10Y-
Dividend Ex-Date-Quick Ratio10.82Sales Y/Y TTM7.89%Profit Margin-126.33%RSI (14)41.56Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.82EPS Q/Q-96.67%SMA20-3.90%Beta0.81Target Price40.67
Payout0.00%Debt/Eq0.10Sales Q/Q-92.59%SMA50-9.28%Rel Volume1.06Prev Close23.14
Employees299LT Debt/Eq0.06EarningsAug 06SMA2001.44%Avg Volume661.21KPrice23.14
IPO DateApr 28, 2017Option/ShortYes / YesEPS/Sales Surpr.-490.00% -91.67%Net Debt/EBITDA2.41Volume699,014Change0.00%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-09-26ReiteratedTruist Financial$40 → $28
Jun-03-26ReiteratedH.C. WainwrightBuy$26 → $46
Mar-09-26ReiteratedEvercore ISI$33 → $48
Dec-17-25InitiatedTruistBuy$40
Dec-12-25UpgradeWells FargoEqual Weight → Overweight$25 → $33
Dec-03-25InitiatedCitizens JMPOutperform$32
Nov-19-25ReiteratedStifel NicolausBuy$28 → $40
Nov-19-25ReiteratedWells FargoEqual Weight$12 → $25
Nov-17-25ReiteratedLeerink PartnersOutperform$24 → $37
Oct-14-25ReiteratedH.C. WainwrightBuy$12 → $26
Latest News
Jun-15-26
Jun-15-2602:48AM
Reported Sunday, Zymeworks Presents Phase 1 Data For ZW191 ADC Showing 78.6% cORR In FRα-Positive And 47.4% In FRα-Negative Platinum-Resistant Ovarian Cancer Patients At ESMO 2026Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue8210676
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A500
Gross Profit7810676
Selling, General and Administrative Excl. Other15,1126262
Research and Development2,509137135
Other Operating Expense-17,430016
Operating Income-114-93-137
Interest Expense
200
Unusual Expense
———
Non-Operating Income (Expense)-10-13-17
Net Income Before Taxes-103-80-117
Income Taxes-116
Consolidated Net Income-103-81-123
Net Income From Continuing Operations-103-81-123
Net Income-103-81-123
EPS (Recurring)-1.37-1.08-1.62
EPS (Basic, Before Extraordinaries)-1.37-1.08-1.62
EPS (Diluted)-1.37-1.08-1.62
EBITDA-94-69-109
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio21.1618.63—
Gross Margin95.12100.00100.00
Operating Margin-139.02-87.74-180.26
Net Margin-125.61-76.42-161.84
Shares Outstanding757576
Market Capitalization1,7361,975—
Operating Lease Expense
———
Insider Trading Volume
$25.39$22.97$20.55$18.13$15.71● Close Price0.00M0.85M1.69M2.54M3.39MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hollywood MarkEVP & Chief Operating OfficerJan 12 '26Option Exercise0.0035,3320139,033Jan 13 12:00 AM
Hollywood MarkEVP & Chief Operating OfficerJan 12 '26Sale22.676,120138,762132,913Jan 13 12:00 AM
Smith Jeffrey T LEVP & Chief Medical OfficerJan 12 '26Sale22.679,310211,09026,708Jan 12 12:00 AM
Smith Jeffrey T LEVP & Chief Medical OfficerJan 12 '26Option Exercise0.0035,332036,018Jan 12 12:00 AM
Moore Paul AndrewChief Scientific OfficerJan 12 '26Option Exercise0.0035,332058,057Jan 12 12:00 AM
Moore Paul AndrewChief Scientific OfficerJan 12 '26Sale22.679,560216,75948,497Jan 12 12:00 AM
Galbraith KennethChair & CEOJan 12 '26Option Exercise0.00128,0000257,266Jan 12 12:00 AM
Galbraith KennethChair & CEOJan 12 '26Sale22.6730,424689,819226,842Jan 12 12:00 AM
Smith Jeffrey T LEVP & Chief Medical OfficerJan 05 '26Option Exercise0.0040,000028,890Jan 05 12:00 AM
Smith Jeffrey T LEVP & Chief Medical OfficerJan 05 '26Sale25.1010,538264,47118,352Jan 05 12:00 AM
Galbraith KennethChair & CEOJan 05 '26Option Exercise0.00228,6680224,952Jan 05 12:00 AM
Galbraith KennethChair & CEOJan 05 '26Sale25.1054,3431,363,840158,286Jan 05 12:00 AM
Moore Paul AndrewChief Scientific OfficerJan 05 '26Option Exercise0.0074,336051,212Jan 05 12:00 AM
Moore Paul AndrewChief Scientific OfficerJan 05 '26Sale25.1020,110504,69931,212Jan 05 12:00 AM
Galbraith KennethChair & CEODec 22 '25Option Exercise0.00200,0000180,803Dec 22 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR